Israel Active

(Thanks to Israel21c) The US FDA has just approved ForeseeHome, developed by Israel’s Notal Vision, which allows patients suffering age-related macular degeneration (AMD) to monitor the progression of the condition in their own homes. It is vital to identify immediately when “dry” AMD changes to “wet” AMD at which point they can be treated.

The US FDA has just approved the home administration of Teva’s Synribo (omacetaxine mepesuccinate). Physicians who treat adults with chronic or accelerated phase Chronic Myeloid Leukemia (CML) can now administer Synribo therapy in the patient’s own home.

The implant-able shunt developed by Israel’s V Wave treats congestive heart failure patients by reducing pressure on the muscle controlling the blood flow between the heart chambers. The first patient to receive the shunt is already experiencing an improved condition.

Japan’s Takeda has signed a deal to commercialize Teva’s innovative treatment for Parkinson’s disease, rasagiline, for use in Japan. It follows Takeda’s deal in Dec 2013 to develop Teva’s glatiramer acetate for the treatment of multiple sclerosis.

Israel’s Teva reported success in a Phase III clinical trial for its abuse-deterrent extended-release CEP-33237 treatment for chronic low back pain. The results showed significant improvement as measured by both weekly average Worst Pain Intensity and weekly Average Pain Intensity scores.

Using the Alpha-P1 Glassia treatment from Israel’s Kamada, sufferers of inherited emphysema can reduce the weekly time taken for infusions down from 70 minutes to just 15. It greatly improves their quality of life.

(Thanks to NoCamels.com) Israeli biotech StartletDerma has developed a unique system for directing skin cosmetic ingredients deep within the skin where they can be most effective. Inocyte contains micro-injectors from the sea anemone to penetrate the skin and make channels for the cosmetics.

Attacks of epilepsy that have been brought on by head injury could be prevented using a new treatment developed by a team including scientists from Ben-Gurion University. In laboratory tests, Losartan (marketed as Cozaar) significantly cut down seizures.

For the first time ever, Israel Technion scientists have transplanted engineered muscle tissue containing major blood vessels to repair a damaged abdomen. The breakthrough may lead to full abdominal surgery in humans using laboratory-generated tissue.

Hebrew University of Jerusalem geneticists have identified how different species of animals can have so many identical genes. Genes are silenced by on/off patterns in the epigenome. They also explain how twins with identical DNA sequences can have so many different characteristics.